Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Medicenna Therapeutics Corp is a biotechnology business based in the US. Medicenna Therapeutics Corp shares (MDNA) are listed on the NASDAQ and all prices are listed in US Dollars. Medicenna Therapeutics Corp employs 13 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $1.19 |
|---|---|
| 52-week range | $0.76 - $3.69 |
| 50-day moving average | $1.03 |
| 200-day moving average | $1.66 |
| Wall St. target price | $7.98 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.36 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.19 from 2022-06-29
| 1 week (2022-06-23) | 11.21% |
|---|---|
| 1 month (2022-05-27) | 17.82% |
| 3 months (2022-03-28) | -8.46% |
| 6 months (2021-12-30) | -28.31% |
| 1 year (2021-06-30) | -60.47% |
|---|---|
| 2 years (2020-06-30) | -67.22% |
| 3 years (2019-06-28) | 5.31% |
| 5 years (2017-06-26) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -50.17% |
| Return on equity TTM | -87.05% |
| Profit margin | 0% |
| Book value | $0.43 |
| Market capitalisation | $60.1 million |
TTM: trailing 12 months
We're not expecting Medicenna Therapeutics Corp to pay a dividend over the next 12 months.
Over the last 12 months, Medicenna Therapeutics Corp's shares have ranged in value from as little as $0.76 up to $3.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Medicenna Therapeutics Corp's is 0.4301. This would suggest that Medicenna Therapeutics Corp's shares are less volatile than average (for this exchange).
Medicenna Therapeutics Corp. , a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA55, which has completed Phase 2b clinical trial to treat rGBM; MDNA109, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease (GvHD); MDNA413, a dual IL-4/IL-13 antagonist to treat solid tumors; and MDNA132, an IL-13 Superkine to chimeric antigen receptor T (CAR-T) platform. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, or naked IL-2, IL-4, and IL-13 Superkines. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.